Hummingbird Diagnostics GmbH to Unveil Pioneering Alzheimer's Disease Biomarker Research at CTAD Conference



More Information



HEIDELBERG, Germany, October 25, 2023 – Hummingbird Diagnostics GmbH, a leader in blood-based small RNA detection and characterization, today announced the presentation of groundbreaking research data at the Clinical Trials in Alzheimer's Disease (CTAD) conference in Boston.

The company has applied its state-of-the-art "mirCator" platform to answer critical questions related to Alzheimer's disease. AI-powered mirCator provides deep insights through the integrated analysis of both disease & immune system derived small RNAs that was initially deployed for early detection of lung cancer (published in JTO 2023).

The featured work in Alzheimer’s disease was made possible through funding by the Alzheimer’s Drug Discovery Foundation (ADDF) and collaboration with researchers from the European Prevention of Alzheimer’s Dementia Consortium (EPAD) and their comprehensive multinational study that enrolled more than 1,800 individuals at risk for Alzheimer's disease.

“We’re thrilled to present our latest research at CTAD, one of the world’s leading conferences on Alzheimer’s disease,” said Dr. Bruno Steinkraus, Chief Scientific Advisor at Hummingbird Diagnostics. “As an additional component to the amyloid tau framework, our biomarkers have the potential to revolutionize the way Alzheimer's is detected and monitored, leading to earlier diagnosis and more effective treatment.”

“Our mirCator platform sets new standards for blood-based small RNA handling, processing, analysis, and characterization,” added Dr. Rastislav Horos, Chief Technology Officer of Hummingbird Diagnostics. “It combines proprietary wet lab innovations, largely automated workflows and advanced machine learning data analysis to deliver unprecedented technical performance.”


About the mirCator platform

Much like the 16th century cartographer Mercator who devised a new way of depicting the world on a flat plane and mapped the world, Hummingbird’s mirCator platform breaks new ground and sets the standard for analyzing and mapping small RNAs from blood.

This holds the potential for early disease detection, disease-specific prognostics, treatment response prediction, and the development of patient-centric therapies.


About Hummingbird Diagnostics GmbH

Hummingbird extracts deep insights into disease through the integrated analysis of both tumor and immune system derived small RNA biomarkers from whole blood.

This dual interrogation of signal from disease and the host response to disease enables the highly sensitive, robust, and AI powered mirCator platform that is poised to revolutionize how we diagnose, treat, and manage cancer and other diseases. 


Media contact:

MacDougall Advisors

Karen Sharma